Category: Principal Investigator

1. Koning JJ, et al.. A Multi-Organ-on-Chip Approach to Investigate How Oral Exposure to Metals Can Cause Systemic Toxicity Leading to Langerhans Cell Activation in Skin. Front Toxicol. 2022. 15;3:824825.
2. A Reconstructed Human Melanoma-in-Skin Model to Study Immune Modulatory and Angiogenic Mechanisms Facilitating Initial Melanoma Growth and Invasion. Michielon E, López González M, Stolk DA, Stolwijk JGC, Roffel S, Waaijman T, Lougheed SM, de Gruijl TD, Gibbs S.Cancers (Basel). 2023 May 20;15(10):2849. doi: 10.3390/cancers1510284
3. Shang, L., et al., Commensal and Pathogenic Biofilms Alter Toll-Like Receptor Signaling in Reconstructed Human Gingiva.Front Cell Infect Microbiol. 2019 Aug 7;9:282. doi: 10.3389/fcimb.2019.00282. eCollection 2019
4. Vahav, I., et al., Reconstructed human skin shows epidermal invagination towards integrated neopapillae indicating early hair follicle formation in vitro. J Tissue Eng Regen Med. doi:10.1002/term.3039 2020
5. Kosten, I.J., et al., MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure. Appl. Pharmacol, 2015. 287(1): p. 35-42.

Imaging mass cytometry in preclinical studies of lung cancer. F. van Maldegem
Book chapter in: “Revealing Uncharted Biology With Single Cell Multiplex Proteomic Technologies|”, Elsevier, edited by W. Fantl. 2024 Jun 25

Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer.
Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, Grigoriadis K, Pich O, Karasaki T, Hobson PS, Levi D, Veeriah S, Puttick C, Nye EL, Green M, Dijkstra KK, Shimato M, Akarca AU, Marafioti T, Salgado R, Hackshaw A; TRACERx consortium; Jamal-Hanjani M, van Maldegem F, McGranahan N, Glass B, Pulaski H, Walk E, Reading JL, Quezada SA, Hiley CT, Downward J, Sahai E, Swanton C, Angelova M. Cancer Discov. 2024 Jun 3;14(6):1018-1047. doi: 10.1158/2159-8290.CD-23-1380.

Mugarza E*, van Maldegem F*, Boumelha J*, Moore C, Rana S, Sopena ML, East P, Ambler R, Anastasiou P, Clavijo PR, Valand K, Cole M, Molina-Arcas M, Downward J. Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers. Science Advances, 2022 July 22;8. doi: 10.1126/sciadv.abm8780

 
Van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nature Communications. 2021 Oct 8;12. doi: 10.1038/s41467-021-26214-x

van Maldegem F, Downward J. Mutant KRAS at the Heart of Tumor Immune Evasion. Immunity. 2020 Jan 14;52(1):14-16. doi: 10.1016/j.immuni.2019.12.013

1. Bogie J.F, Haidar M, Hendriks J.J.A and Kooij G. Fatty acid metabolism in the progression and resolution of CNS disorders. Advanced Drug Delivery Reviews. Conditionally accepted
2. Derada Troletti C, Enzmann G, Chiurchiù V, Haghayegh N, Tietz S, Norris PC, van der Pol SMA, Serhan CN, de Vries HE, Engelhardt B and Kooij G. Pro-resolving lipid mediator Lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifying the spinal cord lipidome. Cell Reports. Conditionally accepted.
3. Kooij G, Derada Troletti C, Leuti A, Norris PC, Riley I, Albanese M, Ruggieri S, Libreros S, van der Pol SMA, van Het Hof B, Schell Y, Guerrera G, Buttari F, Mercuri NB, Centonze D, Gasperini C, Battistini L, de Vries HE, Serhan CN, Chiurchiù V. Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica. 2019 Nov 28. pii: haematol.2019.219519. doi: 10.3324/haematol.2019.219519
4. Kooij G, Kopplin K, Blasig R, Stuiver M, Koning N, Goverse G, van der Pol SM, van Het Hof B, Gollasch M, Drexhage JA, Reijerkerk A, Meij IC, Mebius R, Willnow TE, Müller D, Blasig IE, de Vries HE. Disturbed function of the blood-cerebrospinal fluid barrier aggravates neuro-inflammation. Acta Neuropathol. 2014 Aug 128(2): 267-77
5. Kooij G, Kroon J, Paul D, Reijerkerk A, Geerts D, van der Pol SM, van Het Hof B, Drexhage JA, van Vliet SJ, Hekking LH, van Buul JD, Pachter JS, de Vries HE. P-glycoprotein regulates trafficking of CD8+ T cells to the brain parenchyma. Acta Neuropathol. 2014 May;127(5): 699-7112Aleyd E, van Hout MW, Ganzevles SH, Hoeben KA, Everts V, Bakema JE, van Egmond M. IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I. J Immunol. 2014 Mar 1;192(5):2374-83.

1. van Olst L, Coenen L, Nieuwland JM, Rodriguez-Mogeda C, de Wit NM, Kamermans A, Middeldorp J, de Vries HE. Crossing borders in Alzheimer’s disease: A T cell’s perspective. Adv Drug Deliv Rev. 2022 Sep;188:114398. doi: 10.1016/j.addr.2022.114398. Epub 2022 Jun 30.PMID: 35780907
   

2. Rodríguez-Lorenzo S, van Olst L, Rodriguez-Mogeda C, Kamermans A, van der Pol SMA, Rodríguez E, Kooij G, de Vries HE. Single-cell profiling reveals periventricular CD56^brightNK cell accumulation in multiple sclerosis. 2022 May 10;11:e73849. doi: 10.7554/eLife.73849.PMID: 35536009 
   

3. Wevers NR, Nair AL, Fowke TM, Pontier M, Kasi DG, Spijkers XM, Hallard C, Rabussier G, van Vught R, Vulto P, de Vries HE, Lanz HL. Modeling ischemic stroke in a triculture neurovascular unit on-a-chip. Fluids Barriers CNS. 2021 Dec 14;18(1):59. doi: 10.1186/s12987-021-00294-9.PMID: 34906183
   

4. Rodríguez-Lorenzo S, Ferreira Francisco DM, Vos R, van Het Hof B, Rijnsburger M, Schroten H, Ishikawa H, Beaino W, Bruggmann R, Kooij G, de Vries HE. Altered secretory and neuroprotective function of the choroid plexus in progressive multiple sclerosis.Acta Neuropathol Commun. 2020 Mar 19;8(1):35. doi: 10.1186/s40478-020-00903-y.PMID: 32192527
   

5. Wouters E, de Wit NM, Vanmol J, van der Pol SMA, van Het Hof B, Sommer D, Loix M, Geerts D, Gustafsson JA, Steffensen KR, Vanmierlo T, Bogie JFJ, Hendriks JJA, de Vries HE. Liver X Receptor Alpha Is Important in Maintaining Blood-Brain Barrier Function.Front Immunol. 2019 Jul 31;10:1811. doi: 10.3389/fimmu.2019.01811. eCollection 2019.PMID: 31417573 
   

1. van der Meijs NL, Travecedo MA, Marcelo F, van Vliet SJ. The pleiotropic CLEC10A: implications for harnessing this receptor in the tumor microenvironment. Expert Opin Ther Targets. 2024 Jul 3:1-12. doi: 10.1080/14728222.2024.2374743.
2. van der Haar Àvila I, Zhang T, Lorrain V, de Bruin F, Spreij T, Nakayama H, Iwabuchi K, García-Vallejo JJ, Wuhrer M, van Kooyk Y, van Vliet SJ. Limited impact of cancer-derived gangliosides on anti-tumor immunity in colorectal cancer. Glycobiology. 2024 May 26;34(7):cwae036. doi: 10.1093/glycob/cwae036.
3. Gabba A, Attariya R, Behren S, Pett C, van der Horst JC, Yurugi H, Yu J, Urschbach M, Sabin J, Birrane G, Schmitt E, van Vliet SJ*, Besenius P*, Westerlind U*, Murphy PV*. MUC1 Glycopeptide Vaccine Modified with a GalNAc Glycocluster Targets the Macrophage Galactose C-type Lectin on Dendritic Cells to Elicit an Improved Humoral Response. J Am Chem Soc. 2023 Jun 21;145(24):13027-13037. doi: 10.1021/jacs.2c12843. *shared last author
4. Cornelissen LAM, Blanas A, van der Horst JC, Kruijssen L, Zaal A, O’Toole T, Wiercx L, van Kooyk Y, van Vliet SJ. Disruption of sialic acid metabolism drives tumor growth by augmenting CD8(+) T cell apoptosis. Int J Cancer. 144(9):2290-2302 (2019)
5. Marcelo F, Supekar N, Corzana F, van der Horst JC, Vuist IM, Live D, Boons GPH, Smith DF, van Vliet SJ. Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands. J Biol Chem. 294(4):1300-1311 (2019).
6. Blanas A, Cornelissen LAM, Kotsias M, van der Horst JC, van de Vrugt HJ, Kalay H, Spencer DIR, Kozak RP, van Vliet SJ. Transcriptional activation of fucosyltransferase (FUT) genes using the CRISPR-dCas9-VPR technology reveals potent N-glycome alterations in colorectal cancer cells. Glycobiology. 29(2):137-150 (2019)
7. Blanas A, Sahasrabudhe NM, Rodríguez E, van Kooyk Y and van Vliet SJ. Fucosylated antigens in cancer: an alliance towards tumor progression, metastasis and resistance to chemotherapy. Front Oncol. 8:39 (2018)
   This article was selected for a special edition for World Cancer day 2019, highlighting a selection of top articles published in Frontiers in Oncology over the prior 12 months.
8. Lenos K, Goos JACM, Vuist IM, den Uil SH, Delis-van Diemen PM, Belt EJTh, Stockmann HBAC, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJA, van Vliet SJ. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients Oncotarget 6(28):26278-90 (2015) ‒ IF 5.2, corresponding author

1. Gago da Graça C, van Baarsen LGM, Mebius RE. Tertiary Lymphoid Structures: Diversity in Their Development, Composition, and Role. J Immunol. 2021 Jan 15;206(2):273-281.
2. Nadafi R, Gago de Graça C, Keuning ED, Koning JJ, de Kivit S, Konijn T, Henri S, Borst J, Reijmers RM, van Baarsen LGM, Mebius RE.  Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells and Control Autoreactive T and B Cell Responses. Cell Rep. 2020 Mar 24;30(12):4110-4123.
3. Bar-Ephraim YE, Koning JJ, Burniol Ruiz E, Konijn T, Mourits VP, Lakeman KA, Boon L, Bögels M, van Maanen JP, Den Haan JMM, van Egmond M, Bouma G, Reijmers RM, Mebius RE. CD62L Is a Functional and Phenotypic Marker for Circulating Innate Lymphoid Cell Precursors. J Immunol. 2019 Jan 1;202(1):171-182.
4. Bar-Ephraim YE*, Cornelissen F*, Papazian N, Konijn T, Hoogenboezem RM, Sanders MA, Westerman BA, Gönültas M, Kwekkeboom J, Den Haan JMM, Reijmers RM, Mebius RE*, Cupedo T*. 2017. Cross-Tissue Transcriptomic Analysis of Human Secondary Lymphoid Organ-Residing ILC3s Reveals a Quiescent State in the Absence of Inflammation. Cell Rep. 21(3):823-833. * Equal contribution.
5. Koning JJ, Konijn T, Lakeman KA, O’Toole T, Kenswil KJ, Raaijmakers MH, Michurina TV, Enikolopov G, Mebius RE. 2016. Nestin-Expressing Precursors Give Rise to Both Endothelial as well as Nonendothelial Lymph Node Stromal Cells. J Immunol. 197:2686-94. 

1. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets. Duinkerken S, Horrevorts SK, Kalay H, Ambrosini M, Rutte L, de Gruijl TD, Garcia-Vallejo JJ, van Kooyk Y. Theranostics. 2019 Aug 12;9(20):5797-5809. doi: 10.7150/thno.35059
2. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018 Feb 5. doi: 10.1038/nri.2018.3.
3. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.Perdicchio M, Ilarregui JM, Verstege MI, Cornelissen LA, Schetters ST, Engels S, Ambrosini M, Kalay H, Veninga H, den Haan JM, van Berkel LA, Samsom JN, Crocker PR, Sparwasser T, Berod L, Garcia-Vallejo JJ, van Kooyk Y, Unger WW.  Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3329-34.
4. Glycan modification of antigen alters its intracellular routing in dendritic cells, promoting priming of T cells.Streng-Ouwehand I, Ho NI, Litjens M, Kalay H, Boks MA, Cornelissen LA, Kaur Singh S, Saeland E, Garcia-Vallejo JJ, Ossendorp FA, Unger WW, van Kooyk Y. Elife. 2016 Mar 21;5. pii: e11765. doi: 10.7554/eLife.11765.
5. Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells Perdicchio M, Cornelissen LA, Streng-Ouwehand I, Engels S, Verstege MI, Boon L, Geerts D, Unger WW, van Kooyk Y. Oncotarget. 2016 Jan 5. doi: 10.18632/oncotarget.6822.

1. A. Kamermans, M. Rijnsburger, A. Chakraborty, S. van der Pol, H.E. de Vries*, J. van Horssen*. Reduced Angiopoietin-Like 4 Expression in Multiple Sclerosis Lesions Facilitates Lipid Uptake by Phagocytes via Modulation of Lipoprotein-Lipase Activity. *Authors contribute equally. Front Immunol. 2019 May 3;10:950.
2. C.E. Leurs, P. Podlesniy, R. Trullas, L. Balk, M.D. Steenwijk, A. Malekzadeh, F. Piehl, B.M. Uitdehaag, J. Killestein, J. van Horssen*, C.E. Teunissen*. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. Mult. Scler. 2018 4:472-480
3. .G. Nijland, R.J. Molenaar, S.M. van der Pol, P. van der Valk, C.J. van Noorden, H.E. de Vries, J. van Horssen. Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions. Acta Neuropathol Commun. 2015, 1:79
4. P.G. Nijland, M.E. Witte, B. van Het Hof, S. van der Pol, J. Bauer, H. Lassmann, P. van der Valk, H.E. de Vries, J. van Horssen. Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis.Acta Neuropathol. Commun. 2014 1:170
5. M.E. Witte, P.G. Nijland, J.A. Drexhage, W. Gerritsen, D. Geerts, B. van het Hof, A. Reijerkerk, H.E. de Vries, P. van der Valk, J. van Horssen. Reduced expression of PGC-1alpha partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol. 2013, 2:231-243

1. Affandi, A.J., Grabowska, J.,  Olesek, K.,  Lopez Venegas M., Barbaria, A., Rodríguez, E.,  Mulder, P.P.G., Pijffers, H.J.,  Ambrosini, M., Kalay, H., O’Toole, T., Zwart, E.S., Kazemier, G., Nazmi, K., Bikker, F.J.,  Stöckl, J., van den Eertwegh, A.J.M., de Gruijl, T.D., Storm, G.,  van Kooyk, Y., den Haan, J.M.M. 2020.
   Selective tumor antigen vaccine delivery to human CD169⁺ antigen presenting cells using ganglioside-liposomes. PNAS accepted. We show in this paper that liposomes that contain gangliosides can bind to human CD169+ dendritic cells and are presented to T cells.
2. van Dinther, D., H. Veninga, S. Iborra, E. G. F. Borg, L. Hoogterp, K. Olesek, M. R. Beijer, S. T. T. Schetters, H. Kalay, J. J. Garcia-Vallejo, K. L. Franken, L. B. Cham, K. S. Lang, Y. van Kooyk, D. Sancho, P. R. Crocker, and J. M. M. den Haan. 2018.
   Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8+ T Cell Cross-Priming. Cell Rep 22: 1484-1495. In this paper we describe that CD169 enables adhesion and antigen transfer to cross-presenting dendritic cells and that DNGR-1 mediated activation stimulates cross-presentation.  PMID: 29425504
3. Veninga, H., E. G. Borg, K. Vreeman, P. R. Taylor, H. Kalay, K. Y. van, G. Kraal, L. Martinez-Pomares, and J. M. den Haan. 2015.
   Antigen targeting reveals splenic CD169 macrophages as promoters of germinal center B-cell responses.
   Eur. J. Immunol 45: 747-757. In this paper we show that antigen targeting to CD169⁺macrophages stimulates strong germinal center B cell responses and that CD169⁺ macrophages retain intact antigen on their surface for two days. PMID: 25487358
4. Backer, R., T. Schwandt, M. Greuter, M. Oosting, F. Jungerkes, T. Tuting, L. Boon, T. O’Toole, G. Kraal, A. Limmer, and J. M. den Haan. 2010.
   Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells.
   Proc. Natl. Acad. Sci. U. S. A 107: 216-221. This is our first paper showing that antigens are transferred from CD169⁺macrophages to cross-presentation DCs for CD8⁺ T cell activation. PMID: 20018690
5. den Haan, J. M., S. M. Lehar, and M. J. Bevan.
   CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med 192: 1685-1696. This paper is the first demonstration that CD8⁺DCs (currently named cDC1) selectively cross-present cell-associated antigens. PMID: 11120766

1. Crommentuijn MHW, Schetters STT, Dusoswa SA, Kruijssen LJW, Garcia-Vallejo JJ, van Kooyk Y. Immune involvement of the contralateral hemisphere in a glioblastoma mouse model. J Immunother Cancer. 2020; 8 (1): e000323.
2. Dusoswa SA, Verhoeff J, (…), Garcia-Vallejo JJ. Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin. Proc Natl Acad Sci U S A. 2020; 117 (7): 3693-3703.
3. Dusoswa SA, (…), Garcia-Vallejo JJ. Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells. J Extracell Vesicles. 2019; 8 (1): 1648995.
4. Dusoswa SA, Verhoeff J, Garcia-Vallejo JJ. OMIP-054: Broad Immune Phenotyping of Innate and Adaptive Leukocytes in the Brain, Spleen, and Bone Marrow of an Orthotopic Murine Glioblastoma Model by Mass Cytometry. Cytometry A. 2019; 95 (4): 422-426.
5. Duinkerken S, van Kooyk Y, Garcia-Vallejo JJ. Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future. Oncoimmunology. 2016; 5 (9): e1214791.